Oruka Therapeutics, Inc.: Q4 2025 results
Published 12. 3. 2026, after the market closes. EPS -0,45 $ against an estimate of -0,62.
AI summary
AIThe summary shows how the results turned out, what the company delivered, the pros and cons and why the stock reacted the way it did. We do not have a press release for this quarter yet, so the summary would be based on the numbers alone.